AstraZeneca: promising results for Imfinzi

(CercleFinance.com) - AstraZeneca announces that a phase III trial has shown that Imfinzi (durvalumab) + platinum-based chemotherapy, followed by a combination of Imfinzi and Lynparza, or Imfinzi alone as maintenance therapy, both demonstrated a statistically and clinically significant improvement in progression-free survival (PFS) compared to standard chemotherapy alone, in patients with newly diagnosed advanced or recurrent endometrial cancer.


A superior clinical benefit was observed with the combination of Imfinzi and Lynparza in maintenance treatment, the company said.

Overall survival (OS) data were immature at the time of this analysis, however, a favourable trend was observed for both treatment regimens, AstraZeneca added.


Copyright (c) 2023 CercleFinance.com. All rights reserved.